ITGA1 and neoplasm: Together with our results demonstrating that ITGA1 inhibition sensitizes PDAC cells to gemcitabine-induced cytotoxicity (Fig. 5G and Supplemental Fig. 3A), ITGA1 represents a key new target for sensitizing both primary and metastatic tumor cells to currently available therapeutic strategies.